– USA, CA – Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Dr. Lorianne Masuoka, M.D., to its Board of Directors, effective immediately.
“We are delighted to welcome Dr. Masuoka to the Opiant Board of Directors,” said CEO, Dr. Roger Crystal. “Dr. Masuoka’s extensive experience successfully expanding the depth and value of development pipelines of several biotech companies will be incredibly valuable to Opiant as we advance our mission to develop new medicines for the potential treatment of addictions and drug overdose.”
Dr. Masuoka will establish and chair a science and technology Board Committee.
About Dr. Lorianne Masuoka
Dr. Masuoka has more than 20 years of experience building and expanding high-value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist who has successfully created and overseen high-performing teams lead the clinical development of new medicines, with a focus on neurology, oncology, and pain. Dr. Masuoka served as chief medical officer of InVivo Therapeutics, Cubist Pharmaceuticals, and Nektar Therapeutics where, as a member of executive management, she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, reimbursement, and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics and Chiron. In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc.
“I am excited to join the board of directors at Opiant,” said Dr. Masuoka. “Opiant is working toward solving some of the greatest medical crises facing people worldwide and has several promising programs with the potential to provide transformative treatments to patients suffering the affliction of addiction. I look forward to working alongside the Opiant team and leveraging my experience to develop and deliver on its pipeline.”
Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information: https://www.opiant.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.